Posted by Michael Wonder on 19 Jul 2022
EMA publishes agenda for 18-21 July 2022 CHMP meeting
18 July 2022 - The EMA has published a draft agenda for this week's CHMP meeting.
The CHMP is due to issue opinions for the following technologies:
- Vutrisiran
- Doxorubicin hydrochloride
- Lutetium Lu 177 chloride
- Teriparatide
- tirzepatide
- Nivolumab with relatlimab
- Teclistamab
- Thalidomide
